FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2792141284> ?p ?o ?g. }

• W2792141284 endingPage "1020" @default.
• W2792141284 startingPage "1010" @default.
• W2792141284 abstract "Clinical efficacy of intravitreal anti-VEGF drugs has been widely demonstrated in several angiogenesis-driven eye diseases including diabetic macular edema and the neovascular form of age-related macular degeneration. Pegaptanib, ranibizumab, and aflibercept have been approved for use in the eye, whereas bevacizumab is widely used by ophthalmologists to treat patients off-label. These drugs are active in the nanomolar to picomolar range; however, caution is required when establishing the rank order of affinity and potency due to in vitro inter-experimental variation. Despite the small doses used for eye diseases and the intravitreal route of administration may limit systemic side effects, these drugs can penetrate into blood circulation and alter systemic VEGF with unknown clinical consequences, particularly in vulnerable groups of patients. Clinical pharmacokinetics of ocular anti-VEGF agents should therefore be taken into account when choosing the right drug for the individual patient. The gaps in current understanding that leave open important questions are as follows: (i) uncertainty about which drug should be given first, (ii) how long these drugs can be used safely, and (iii) the choice of the best pharmacological strategy after first-line treatment failure. The current review article, based on the information published in peer-reviewed published papers relevant to anti-VEGF treatments and available on the PubMed database, describes in detail the clinical pharmacology of this class of drugs to provide a sound pharmacological basis for their proper use in ophthalmology clinical practice." @default.
• W2792141284 created "2018-03-29" @default.
• W2792141284 creator A5007609959 @default.
• W2792141284 creator A5030848899 @default.
• W2792141284 creator A5053492340 @default.
• W2792141284 creator A5068107707 @default.
• W2792141284 creator A5083693387 @default.
• W2792141284 creator A5085804289 @default.
• W2792141284 date "2018-02-05" @default.
• W2792141284 modified "2023-10-13" @default.
• W2792141284 title "Clinical pharmacology of intravitreal anti-VEGF drugs" @default.
• W2792141284 cites W1500728559 @default.
• W2792141284 cites W1504850949 @default.
• W2792141284 cites W1555969666 @default.
• W2792141284 cites W1576012659 @default.
• W2792141284 cites W1656005130 @default.
• W2792141284 cites W1786299986 @default.
• W2792141284 cites W1802218256 @default.
• W2792141284 cites W1851059930 @default.
• W2792141284 cites W1872446387 @default.
• W2792141284 cites W1875554126 @default.
• W2792141284 cites W1916772698 @default.
• W2792141284 cites W1964901573 @default.
• W2792141284 cites W1976005612 @default.
• W2792141284 cites W1980725734 @default.
• W2792141284 cites W1985388968 @default.
• W2792141284 cites W1995044506 @default.
• W2792141284 cites W1995595526 @default.
• W2792141284 cites W1996171994 @default.
• W2792141284 cites W1996684935 @default.
• W2792141284 cites W2003418160 @default.
• W2792141284 cites W2009964074 @default.
• W2792141284 cites W2010456772 @default.
• W2792141284 cites W2010672933 @default.
• W2792141284 cites W2014148719 @default.
• W2792141284 cites W2018291910 @default.
• W2792141284 cites W2018822308 @default.
• W2792141284 cites W2019061836 @default.
• W2792141284 cites W2021075914 @default.
• W2792141284 cites W2033550192 @default.
• W2792141284 cites W2034029819 @default.
• W2792141284 cites W2034060643 @default.
• W2792141284 cites W2038451782 @default.
• W2792141284 cites W2041322618 @default.
• W2792141284 cites W2042034090 @default.
• W2792141284 cites W2048433984 @default.
• W2792141284 cites W2051869883 @default.
• W2792141284 cites W2052204551 @default.
• W2792141284 cites W2057983131 @default.
• W2792141284 cites W2059050919 @default.
• W2792141284 cites W2062907983 @default.
• W2792141284 cites W2072011053 @default.
• W2792141284 cites W2075093438 @default.
• W2792141284 cites W2076151830 @default.
• W2792141284 cites W2077825350 @default.
• W2792141284 cites W2079345992 @default.
• W2792141284 cites W2079843091 @default.
• W2792141284 cites W2081930185 @default.
• W2792141284 cites W2083491236 @default.
• W2792141284 cites W2085052834 @default.
• W2792141284 cites W2085712747 @default.
• W2792141284 cites W2089331342 @default.
• W2792141284 cites W2092122582 @default.
• W2792141284 cites W2092886764 @default.
• W2792141284 cites W2093044616 @default.
• W2792141284 cites W2093646832 @default.
• W2792141284 cites W2096136598 @default.
• W2792141284 cites W2096547439 @default.
• W2792141284 cites W2100864621 @default.
• W2792141284 cites W2102167881 @default.
• W2792141284 cites W2102463203 @default.
• W2792141284 cites W2111502329 @default.
• W2792141284 cites W2114441193 @default.
• W2792141284 cites W2122189616 @default.
• W2792141284 cites W2124415048 @default.
• W2792141284 cites W2139927762 @default.
• W2792141284 cites W2140641836 @default.
• W2792141284 cites W2142819846 @default.
• W2792141284 cites W2144771657 @default.
• W2792141284 cites W2144846819 @default.
• W2792141284 cites W2146250664 @default.
• W2792141284 cites W2148060211 @default.
• W2792141284 cites W2152816807 @default.
• W2792141284 cites W2153192092 @default.
• W2792141284 cites W2154073405 @default.
• W2792141284 cites W2154181208 @default.
• W2792141284 cites W2154200023 @default.
• W2792141284 cites W2154770697 @default.
• W2792141284 cites W2156113162 @default.
• W2792141284 cites W2157501021 @default.
• W2792141284 cites W2161588304 @default.
• W2792141284 cites W2175768232 @default.
• W2792141284 cites W2187754395 @default.
• W2792141284 cites W2226008915 @default.
• W2792141284 cites W2289200040 @default.
• W2792141284 cites W2292667920 @default.
• W2792141284 cites W2319565025 @default.
• W2792141284 cites W2320436848 @default.

• next